Abstract 148P
Background
The purpose of this study was to compare Capecitabine and Oxaliplatin (XELOX) with S-1, based on disease-free survival (DFS) and overall survival (OS) in gastric cancer (GC). In addition, clinical impact of using lymph node ratios and compare it with N stage was investigated.
Methods
Patients who had curative resection and received either S-1 or XELOX as adjuvant chemotherapy for advanced gastric cancer between Jan, 2011 and Dec, 2015, were analysed. Of the 412 patients enrolled, 301 received S-1 and 111 received XELOX. Lymph node ratio (LNR) groups were segregated as 0, 0-0.1, 0.1-0.25, and > 0.25 and named LNR 0,1,2 and 3, respectively. Propensity score matching (PSM) was used to minimize the influence of potential selection bias. The PSM compared DFS and OS in the two treatment groups, and enabled subgroup analysis according to clinical variables including the lymph node ratio group (LNR group) and N stage.
Results
In PSM cohort, the sample size of each group was 86 patients and variables are well balanced. The XELOX group showed significantly better DFS (26.9% vs 59.3%, HR 0.43, 95% CI 0.20-0.90; p = 0.025) and better OS(30.8% vs 63.0%, HR 0.44, 95% CI 0.20-0.99; 0.045) in stage IIIC. The XELOX group showed significantly better DFS in all stage III. (54.7% vs 61.6%, HR 0.57 ,95% CI 0.33-0.99; p = 0.045). The N3 group showed significantly better DFS (40% vs 65.8%, HR 0.45, 95% CI, 0.23-0.86; p = 0.017) and better OS (44.7% vs 68.4%, HR 0.48, 95% CI, 0.24-0.97; p = 0.040) in the XELOX group. The LNR 3 group showed significantly better DFS in the XELOX group (26.3% vs 52.9% with HR 0.41 (95% CI, 0.17-0.97; p = 0.042).
Conclusions
Our data suggested that current N staging and LNR could be a useful tool for selecting patients who can benefit from adjuvant XELOX after D2 gastrectomy when compared with S-1. When patients who are designated N3 or LNR > 0.25 or at stage IIIC, XELOX should be recommended over S-1.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract